Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 28, 2021
Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.752 billion during the first quarter of 2021. This represents growth of 8.2 percent on a reported basis, 5.6 percent on an...
-
Mar 26, 2021
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ending March 31, 2021 on Wednesday, April 28,...
Mar 25, 2021Data presented at SIR 2021 confirm safety and dose-efficacy relationshipBoston Scientific Corporation (NYSE: BSX) announced positive data from the TARGET study of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere) – a type of radioembolization comprised of...
Mar 18, 2021Treatment is the only radioembolization treatment approved for U.S. patients with hepatocellular carcinomaBoston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of...
-
Mar 3, 2021Acquisition of a leading laser technology to expand global kidney stone management portfolio
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of...
-
Feb 12, 2021
Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences. On February 25, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie...
-
Feb 3, 2021
Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a reported basis, (8.3) percent on...
Jan 22, 2021Fourth-generation DBS portfolio features full-body MR conditional devicesBoston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System. The...
-
Jan 21, 2021Acquisition of external cardiac monitoring technologies and services provider to expand rhythm management diagnostics portfolio and capabilities
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately-held company which offers a full portfolio of...
- Jan 14, 2021SCS portfolio features largest portfolio of full-body MRI conditional devices that combine therapy options for personalized pain relief
Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) systems. The unified portfolio of four MRI conditional,...
